title: AIDS in the Third World: how to stop the HIV infection?
abstract: Of the 38.6 million people living with HIV/AIDS globally, almost 25 million (65%) live in sub-Saharan Africa. Preventive strategies and measures fall short, often simply because they are not available or are largely male-controlled. A preventive HIV vaccine is still far away; hence the drive to develop alternative prevention technologies, such as microbicides and oral pre-exposure prophylaxis, that could be female controlled. There are, at present, twenty-two anti-HIV drugs which have been formally licensed for clinical use in the treatment of HIV infections (AIDS): zidovudine, didanosine, zalcitabine, stavudine, lamivudine, abacavir, emtricitabine, tenofovir, nevirapine, delavirdine, efavirenz, saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, lopinavir, atazanavir, fosamprenavir, tipranavir, darunavir and enfuvirtide. These compounds, in combination, form the basis of HAART (highly active antiretroviral therapy), which has led to the development of a single daily pill existing of the combination of tenofovir disoproxil fumarate, emtricitabine and efavirenz, which has to be taken orally once daily for the treatment of AIDS. Beyond development of new drugs and clinical evaluation of existing medications, several companies within the pharmaceutical industry have established innovative policies that provide HIV medications at affordable prices in the least-developed countries. Reduced pricing is not alone a solution, and thus companies are actively working in partnership with the World Health Organization and other multinational groups to address roadblocks such as complex registration and procurement systems. Even in this period of successful anti-HIV therapy via HAART, a growing number of patients is cycling through the various remaining therapeutic options and are increasingly becoming dependent of the availability of newly developed anti-HIV agents. It is of concern that existing and future therapies will have to be effective against newly evolving (including drug-resistant) HIV variants in patients who currently face many years, if not decades, of chronic anti-HIV drug treatment. In spite of continuous long-term interventions to promote safer sexual behaviour, HIV prevalence is high and still rising in many parts of the world. The face of the epidemic is now black, female, young and poor..., and female controlled methods are urgently needed. Female controlled methods such as microbicides and cervical barrier methods provide hopeful perspectives when condom use is low due to social, cultural and/or economic factors, but, after all, the oral administration of a single daily pill would seem the most convenient way to prevent HIV infection, as its protective activity may be independent of the route of viral transmission.
authors.affiliation: Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10 - B 3000 Leuven.
authors.forename: E
authors.initials: E
authors.lastname: De Clercq
mesh_terms: D019380:Anti-HIV Agents / Q000600:supply & distribution / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D003906:Developing Countries; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission*; D006801:Humans; D008297:Male; D012725:Sexual Behavior; D014944:World Health Organization
chemical_list: D019380:Anti-HIV Agents